Pharmacy Times
NOVEMBER 26, 2024
Pharmacists play a vital role in multidisciplinary health care teams by enhancing medication safety, optimizing therapeutic outcomes, expanding medication access, reducing costs, and improving patient education.
Fierce Healthcare
NOVEMBER 26, 2024
The Centers for Medicare & Medicaid Services (CMS) is attempting to cover anti-obesity medications under Medicare Part D and Medicaid, the agency announced Nov. 26. | With time running out before leaving office, the Biden administration is proposing a rule to have Medicare and Medicaid cover anti-obesity medications and bolster guardrails for AI, among the changes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
NOVEMBER 26, 2024
As a physician, I was taught to appreciate the clinical importance of human touch for our physical and mental health. As a human being, I worry about its loss. And as a dermatologist, I know what that loss may mean for the loneliest and most vulnerable among us. Scientific studies prove that human touch — whether it be a quick hug, holding a baby, or a professional massage — is important to our mental and physical well-being.
Fierce Healthcare
NOVEMBER 26, 2024
The Centers for Medicare & Medicaid Services (CMS) finalized a six-year mandatory model to increase access to kidney transplants, the agency announced Nov. 26. | CMS made some concessions to hospitals who strongly criticized the kidney transplant model proposed rule in May.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
NOVEMBER 26, 2024
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, talks about the best ways pharmacists can stay updated on advancements in diabetes medications and treatments.
Fierce Pharma
NOVEMBER 26, 2024
While Novartis has largely wrapped up its transformation into a leaner innovative medicines company—which included multiple rounds of staff cuts over the years—employment changes are still afoot at | Novartis is laying off a total of 139 staffers in East Hanover, New Jersey, where the company’s U.S. headquarters is located. The move will primarily affect commercial field sales associates working on the brands Xolair for asthma and allergies and the oncology combo made up of kinase inhibitors Taf
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
NOVEMBER 26, 2024
Benjamin Jolley, PharmD, pharmacist at Jolley’s Compounding Pharmacy in Salt Lake City, Utah, discussed the state of independent pharmacy.
STAT
NOVEMBER 26, 2024
New data from a mid-stage study of an Amgen obesity drug showed that it helped participants lose a substantial amount of weight, but questions about how competitive it could be appear to be shaping the response to the news, with the company’s share price falling on the announcement. Amgen said Tuesday that that its drug, MariTide , led to an average of roughly 20% weight loss over a year in the Phase 2 study in participants who had obesity or who were overweight without type 2 diabe
European Pharmaceutical Review
NOVEMBER 26, 2024
Glucagon-like peptide-1 (GLP-1) receptor agonists have shown to provide meaningful benefits in chronic kidney disease (CKD) and individuals with and without diabetes. This based on the largest, most comprehensive analysis of GLP-1 antagonists on kidney and cardiovascular outcomes. While GLP-1 receptor agonists have shown benefit for type 2 diabetes, obesity and cardiovascular disease, its impact as a treatment in chronic kidney disease is not as clear, the researchers explained.
STAT
NOVEMBER 26, 2024
Recursion Pharmaceuticals, one of the most advanced companies using artificial intelligence and machine learning tools to expedite drug development , laid off employees after closing a merger last week.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
NOVEMBER 26, 2024
Researchers aimed to address the associations between gout and ischemic events, specifically ischemic colitis.
STAT
NOVEMBER 26, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. How FDA categories may keep AI from relieving clinician burnout In a counterintuitive result, using AI did not reduce radiologists’ burnout, a recent JAMA Network Open study of over 6,700 radiologists in China found.
pharmaphorum
NOVEMBER 26, 2024
Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline.
STAT
NOVEMBER 26, 2024
LONDON — An experimental cancer treatment from Roche failed to improve survival in a major lung cancer study, the company said Tuesday, a result that will further stoke doubts about the drug’s target. In a short statement, Roche said that a combination of the drug, called tiragolumab, with its existing medicine Tecentriq did not outperform Tecentriq alone on the study’s primary endpoint of overall survival.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
NOVEMBER 26, 2024
German CDMO Adragos Pharma has been on a growth tear this year, drafting plans to boost capacity in Japan, upgrading a facility in France, taking over another from Fresenius Kabi in Norway and more | German CDMO Adragos Pharma has been on a growth tear this year. Now, the manufacturing arriviste—which was founded in 2020—is expanding its production network again with the acquisition of Switzerland's Baccinex, which specializes in fill and finish services.
STAT
NOVEMBER 26, 2024
Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases in the muscle, nervous system, and lung. In addition to the upfront payment, Sarepta will also make a $325 million investment in Arrowhead, pay out $50 million a year for the next five years, and promise $300 million in “near-term” milestone payments related to clinical trial enrollment.
Pharmacy Times
NOVEMBER 26, 2024
Investigators also found that vaccination for those aged 27 to 45 produces a higher number needed to vaccinate.
STAT
NOVEMBER 26, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Tuesday! Adam Feuerstein, here, filling in for your regular Readout correspondents.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
NOVEMBER 26, 2024
In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “am | Shorla Oncology has scored an FDA approval for its strawberry-flavored drink version of Novartis' cancer drug Gleevec. Dubbed Imkeldi, it becomes the first oral liquid form of imatinib.
pharmaphorum
NOVEMBER 26, 2024
Roche has upgraded its partnership with off-the-shelf CAR-T therapy specialist Poseida to a $1 billion-plus takeover bid.
STAT
NOVEMBER 26, 2024
The new class of GLP-1 weight loss drugs have been blockbusters since they arrived on the market a few years ago. These medications have made tens of billions of dollars for drugmakers and have made their way into the public consciousness in a remarkable way. Almost three-quarters of adults in the U.S. are overweight or obese, and obesity can lead to a litany of health complications, including heart disease, joint pain, and cancer.
Pharmaceutical Technology
NOVEMBER 26, 2024
Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
STAT
NOVEMBER 26, 2024
LONDON — Policymakers and scientific groups need to specify guidelines for the burgeoning field that uses stem cells to mimic aspects of embryonic development, including by establishing certain red lines on research, an influential U.K. bioethics group said Wednesday in a new report. Specifically, the report from the Nuffield Council on Bioethics says that researchers should not use these stem cell-based embryo models to try to start a pregnancy in a person or animal, and should not
pharmaphorum
NOVEMBER 26, 2024
ZENITH trial of MSD's Winrevair in PAH could add further momentum to an already impressive launch.
Drug Topics
NOVEMBER 26, 2024
Individuals who received tailored text message reminders about receiving a COVID-19 booster vaccine were more likely to get it.
pharmaphorum
NOVEMBER 26, 2024
Outgoing US President Joe Biden has proposed a dramatic expansion of Medicare coverage of obesity drugs, but will the plan see the light of day?
Pharmacy Times
NOVEMBER 26, 2024
Exposure to pollutants PM2.5 and NO2 was found to increase the likelihood of developing a peanut allergy and of the allergy persisting.
Fierce Healthcare
NOVEMBER 26, 2024
Mount Sinai Health System has opened the doors of its new AI research center in Manhattan, the Hamilton and Amabel James Center for AI and Human Health. | Mount Sinai Health System announced on Tuesday that it opened its Hamilton and Amabel James Center for Artificial Intelligence and Human Health, which will be a research site for AI development.
pharmaphorum
NOVEMBER 26, 2024
Discover the revolutionary impact of generative artificial intelligence (GenAI) on drug safety in pharmacovigilance. Learn how this cutting-edge technology is transforming the industry.
Fierce Healthcare
NOVEMBER 26, 2024
Providers are rapidly adopting generative AI-based clinical documentation tools to aid clinicians and make digital paperwork more efficient. | Cambridge Health Alliance, the only public academic health system in Massachusetts, is deploying Abridge's AI-based medical note-taking tool across its 600 clinicians after a successful pilot.
The FDA Law Blog
NOVEMBER 26, 2024
By Larry K. Houck — Last May the Department of Justice (“DOJ”) and the Drug Enforcement Administration (“DEA”) issued a Notice of Proposed Rulemaking (“NPRM”) to transfer marijuana from schedule I of the Controlled Substances Act (“CSA”) to schedule III. Schedules of Controlled Substances: Rescheduling of Marijuana, 89 Fed. Reg. 44,597 (May 21, 2024).
Compounding Pharmacy of America
NOVEMBER 26, 2024
Learn about the benefits, types, and effectiveness of topical pain relief, including custom compounded gels. Discover how personalized topical solutions can target pain efficiently. The post A Complete Guide to Topical Pain Relief: Benefits, Types, and Customized Solutions appeared first on The Compounding Pharmacy of America.
PharmExec
NOVEMBER 26, 2024
Results of the RESILIENT SMA study found that while taldefgrobep demonstrated clinically meaningful motor function improvements in patients with spinal muscular atrophy, the treatment arm did not achieve statistical significance at 48 weeks.
Expert insights. Personalized for you.
132 
Let's personalize your content